Abstract

BackgroundThe combination of budesonide + formoterol (BFC) offers the advantages of dose adjustment in a single inhaler according to asthma symptoms. We analyzed the relationship between asthma symptoms in terms of peak expiratory flow (PEF) and dose adjustment by the patient.MethodsTwenty-eight patients with asthma who used BFC for alleviation of their symptoms (12 men, 16 women; 60 years old) were instructed that the inhaled BFC dose could be increased to a maximum of 8 inhalations per day according to symptom severity. Patients measured and recorded PEF every morning and evening in their asthma diary along with their symptoms and the dose of drugs taken.ResultsSixteen of the 28 patients increased their dose for asthma symptoms. The time to recovery from the asthma symptoms was significantly shorter when cough was the only symptom present compared with dyspnea or wheeze (1.4 vs. 5.3 or 6.6 days, p < 0.05) and when they had only one symptom compared with two or three symptoms (1.3 vs. 5.7 or 10.5, p < 0.01). The relationship between PEF (% of personal best) when the dose was increased (Y) and the days for the increased dose to achieve a PEF greater than PEF in the symptom-free state (X) was determined to be Y = − 0.591X + 89.2 (r2 = 0.299, p < 0.001).ConclusionAs a guide for increasing the BFC dose when patients with mild asthma have asthma symptoms, the dose should be increased when cough is present or PEF is decreased to 88.9% (i.e., X = 0.5).

Highlights

  • The combination of budesonide + formoterol (BFC) offers the advantages of dose adjustment in a single inhaler according to asthma symptoms

  • Studies have shown that sputum and biopsy eosinophil counts were higher with the use of Symbicort maintenance and reliever therapy (SMART) compared with the use of a high fixed dose of Budesonide + formoterol (BFC), this difference in eosinophil counts has no detrimental effect on the control of asthma [17]

  • We evaluated the peak expiratory flow (PEF) changes and calculated the mean and standard deviation (SD) for each

Read more

Summary

Introduction

The combination of budesonide + formoterol (BFC) offers the advantages of dose adjustment in a single inhaler according to asthma symptoms. One of the advantages of using the combination of budesonide + formoterol (BFC; Symbicort®, Turbuhaler®, AstraZeneca, Osaka, Japan) is that the dose can be adjusted in a single inhaler according to the severity of asthma symptoms [1,2,3]. The results of many other studies are in favor of the use of SMART for controlling the severity of asthma [12,13,14,15,16]. Studies have shown that sputum and biopsy eosinophil counts were higher with the use of SMART compared with the use of a high fixed dose of BFC, this difference in eosinophil counts has no detrimental effect on the control of asthma [17]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call